Ян Кимаковский - Повышенный холестерин. Профилактика и лечение астеросклероза

33. Mendoza-Oliva A., Ferrera P., Arias C. (2013). Interplay Between Cholesterol and Homocysteine in the Exacerbation of Amyloid-β Toxicity in Human Neuroblastoma Cells. CNS Neurol. Disord. Drug Targets;

34. Werder S. F. (2013). Cobalamin deficiency, hyperhomocysteinemia, and dementia. Neuropsychiatr. Dis. Treat. 6, 159–195;

35. T. M. Scott. (2004). Homocysteine and B Vitamins Relate to Brain Volume and White-Matter Changes in Geriatric Patients With Psychiatric Disorders. American Journal of Geriatric Psychiatry. 12, 631–638;

36. Jacobsen D. W. (1998). Homocysteine and vitamins in cardiovascular disease. Clin. Chem. 8, 1833–1843;

37. Annie L. Culver. (2012). Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women’s Health Initiative. Arch Intern Med. 172, 144;

38. Statin use linked to increased risk of diabetes in older women. Risk of type 2 diabetes in postmenopausal women may be up to 48 percent higher than in women who do not use the cholesterol-lowering drugs, but the jury tilts in favor of continuing medication. (2012). Duke Med. Health News. 4, 4–5;

39. Uchechukwu K. Sampson, MacRae F. Linton, Sergio Fazio. (2011). Are statins diabetogenic?. Current Opinion in Cardiology. 26, 342–347;

40. Vienna E. Brunt, Douglas R. Seals, et al. Suppression of the gut microbiome ameliorates age-related arterial dysfunction and oxidative stress in mice. The Journal of Physiology, 2019.

41. ristina Menni et al. Gut microbial diversity is associated with lower arterial stiffness in women – European Heart Journal, Volum 39, Issue 25, 1 July 2018, Pages 2390–2397.

42. Hunter W. Korsmo, et al. Choline: Exploring the Growing Science on Its Benefits for Moms and Babies. Nutrients 2019, 11 (8), 1823.

43. «Cardioprotective mechanism of omega-3 polyunsaturated fatty acids» в Journal of cardiology https://www.journal-of-cardiology.com/article/S0914-5087(15)00230-0/fulltext.

44. «Omega-3 Fatty Acids and Depression: Scientific Evidence and Biological Mechanisms» https://www.hindawi.com/journals/omcl/2014/313570/.

45. «Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes» https://pubmed.ncbi.nlm.nih.gov/26648072/?from_term=Omega-7&from_pos=6.

46. «Dietary Palmitoleic Acid Attenuates Atherosclerosis Progression and Hyperlipidemia in Low-Density Lipoprotein Receptor-Deficient Mice» https://pubmed.ncbi.nlm.nih.gov/30921498/?from_term=Omega-7&from_pos=9.

47. Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants – Archives of Internal Medicine, Vol. 170 No. 12, June 28, 2010.

48. Драпкина О. М., Чернова Е. М., Корнеева О. Н., Первый МГМУ имени И. М. Сеченова. Клиника пропедевтики внутренних болезней Первого МГМУ им. И. М. Сеченова (Директор клиники академик РАМН Ивашкин В. Т.) ресурс – https://medi.ru/info/565/.

49. Медведев Ж. Холестерин: наш друг или враг? Журнал «Наука и жизнь», № 1, № 2 2008;

50. M. N Haan. (2009). Review: statins do not protect against development of dementia. Evidence-Based Mental Health. 12, 114–114.

51. (Рациональное питание. Анохина Г. А.).

52. Joanne M. Murabito, Joseph M. Massaro, Brian Clifford, Udo Hoffmann, Caroline S. Fox. (2013). Depressive symptoms are associated with visceral adiposity in a community-based sample of middle-aged women and men. Obesity. 21, 1713–1719).

53. Durba Sengupta, Amitabha Chattopadhyay. (2012). Identification of Cholesterol Binding Sites in the Serotonin1AReceptor. J. Phys. Chem. B. 116, 12991-12996.

54. (Pushpendra Singh, Sourav Haldar, Amitabha Chattopadhyay. (2013). Differential effect of sterols on dipole potential in hippocampal membranes: Implications for receptor function. Biochimica et Biophysica Acta (BBA) – Biomembranes. 1828, 917–923);

55. (Md. Jafurulla, A. Chattopadhyay. (2012). Membrane Lipids in the Function of Serotonin and Adrenergic Receptors. CMC. 20, 47–55);.

56. Roopali Saxena, Amitabha Chattopadhyay. (2012). Membrane cholesterol stabilizes the human serotonin1A receptor. Biochimica et Biophysica Acta (BBA) – Biomembranes. 1818, 2936–2942.

57. Shultz T. D. and Rose D. P. (1988). Effect of high-fat intake on lactogenic hormone bioactivity in premenopausal women. Am. J. Clin. Nutr. 3, 791–794.

58. Чугунов А. О., Полянский А. А., Ефремов Р. Г. «Липидный фундамент жизни» Природа. 3, 3-12.

59. Lejskova M., Alušík S., Valenta Z., Adámkova S., Pitha J. (2012). Natural postmenopause is associated with an increase in combined cardiovascular risk factors. Physiol. Res. 6, 587–596.

60. Christine M. Williams, Karen Maunder, D. Theale. (1989). The effect of a low-fat diet on luteal-phase prolactin and oestradiol concentrations and erythrocyte phospholipids in normal premenopausal women. Br J Nutr. 61, 651–661.

61. Xiaohui Cui, Bernard Rosner, Walter C. Willett, Susan E. Hankinson. (2010). Dietary Fat, Fiber, and Carbohydrate Intake and Endogenous Hormone Levels in Premenopausal Women. HORM CANC. 1, 265–276.

62. Холестерин // Большая советская энциклопедия: [в 30 т.] / гл. ред. А. М. Прохоров. – 3-е изд. – М.: Советская энциклопедия, 1969–1978.

63. PubMed – NCBI Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis.

64. Ленинджер А. 1976. Биохимия. М.: «Мир».

65. André Tchernof, Fernand Labrie, Alain Bélanger, Denis Prud’homme, Claude Bouchard, et. al.. (1997). Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis. 133, 235–244).

66. Кольман Я., Рём К.-Г., «Наглядная биохимия», пер. с нем., М., «Мир», 2009.

67. Frank M Sacks, Martijn Katan. (2002). Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. The American Journal of Medicine. 113, 13–24.

68. Classics in arteriosclerosis research: On experimental cholesterin steatosis and its significance in the origin of some pathological processes by N. Anitschkow and S. Chalatow, translated by Mary Z. Pelias, 1913. Arteriosclerosis, Thrombosis, and Vascular Biology. 3, 178-182.

69. Ежов М. В., Сергиенко И. В., Рожкова Т. А., Кухарчук В. В., Коновалов Г. А., Мешков А. Н., Ершова А. И., Гуревич В. С., Константинов В. О., Соколов А. А., Щербакова М. Ю., Леонтьева И. В., Бажан С. С., Воевода М. И., Шапошник И. И. Российские рекомендации по диагностике и лечению семейной гиперхолестеринемии. Атеросклероз и дислипидемии. 2016; 4: 21-9.

70. Yuan G., Wang J., Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ. 2006 Apr 11; 174 (8): 1124-9.

71. Goldberg AC., Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adultpatients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5 (3 Suppl): S1-8. doi:10.1016/j.jacl.2011.04.003. Epub 2011 Apr 12.

72. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004 Mar; 173 (1): 55–68.

73. Кухарчук В. В., Малышев П. П., Мешков А. Н. Семейная гиперхолестеринемия: современные аспекты диагностики, профилактики и терапии. Кардиология. 2009; 49 (1): 76–83.

74. Yuan G, Wang J., Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ. 2006 Apr 11; 174 (8): 1124-9.

75. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on FamilialHypercholesterolemia. J Clin Lipidol. 2011 Jun; 5 (3 Suppl): S9-17.

76. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 1993 Dec; 104 (1–2): 1-18.

77. Merino-Ibarra E., Castillo S., Mozas P., Cenarro A., Martorell E., Díaz JL, Suarez-Tembra M., Alonso R., Civeira F., Mata P., Pocoví M.. Screening of APOB gene mutations in subjects with clinical diagnosis of familialhypercholesterolemia. Hum Biol. 2005 Oct; 77 (5): 663-73.

78. Soufi M., Sattler AM, Maerz W., Starke A., Herzum M., Maisch B., Schaefer JR. A new but frequent mutation of apoB-100-apoB His3543Tyr. Atherosclerosis. 2004 May; 74 (1): 11.

79. Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev. 2008 Feb; 29 (1): 11-2.

80. Мандельштам, М. Ю., Васильев В. Б. Моногенные гиперхолестеринемии: новые гены, новые мишени для лечения. Генетика. – 2008. – Т. 44, N 10. – С. 1309–1316.

81. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA. 2005 Feb 8; 102 (6): 2069-74.

82. Ouguerram K., Chetiveaux M., Zair Y., Costet P., Abifadel M., Varret M., Boileau C., Magot T., Krempf M.. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol. 2004 Aug; 24 (8): 1448-53.

83. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In Scriver CR, Beaudet AL, Sly WS, Valle D. eds, The Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York: McGraw-Hill Information Services Company; 2001, p2863 – 2913.

84. Abifadel M., Rabès JP, Devillers M., Munnich A., Erlich D., Junien C., Varret M., Boileau C. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009 Apr; 30 (4): 520-9.

85. Sharifi M., Futema M., Nair D., Humphries SE. Genetic Architecture of Familial Hypercholesterolaemia. Curr Cardiol Rep. 2017 May; 19 (5): 44.

86. Мешков А. И., Ершова А. И., Щербакова Н. В., Рожкова Т. А., Калинина М. В., Малышев П. П., Кухарчук В. В., Бойцов С. А. Фенотипические особенности течения гетерозиготной формы семейной гиперхолестеринемии у носителей мутаций генов LDLR и APOB. Кардиоваскулярная терапия и профилактика 2011; 10 (8): 63–65.

87. Кухарчук В. В. Этиология и патогенез атеросклероза // Руководство по атеросклерозу и ишемической болезни сердца. Под ред. акад. Е. И. Чазова, член-корр. РАМН В. В. Кухарчука, проф. С. А. Бойцова. М.: Медиа Медика, 2007. – 736 с.